Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Depomed
>
Stock price
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 5932959"]Yeah thats all great marketing material, and maybe Arthur uses that in his Q3 earnings call. What Nucynta is doing in Europe has nothing to do with anything unfortunately. Whole diff ball game. Nucynta is no where near as expensive in Europe which is one of the biggest factors here. </p><p><br /></p><p>Despite all these great talking points, the fact of the matter is (and this is from our call last week), scripts are declining. Basically we are looking at it like this:</p><p><br /></p><p>1. The patient has to find a doctor who will actually prescribe Nucynta</p><p>2. The patients has to actually have insurance that will cover it, few can afford Nucynta out of pocket</p><p>3. If the patient finally gets this far they have to find a pharmacy that will fill it</p><p><br /></p><p>So on all 3 fronts you have doctors, insurance companies, and pharmacies all trying to do their part to block a Nucynta sale. Making a sale is a maze, and not everyone is going to get through. Some get #1, but then get suck on #2. #3 is seen as minimal but growing risk with CVS and Walgreens trying to hop on the bandwagon and block peoples meds. Basically at the end of the quarter, the Nucynta script count is total number of people in this country who made it through the maze.</p><p><br /></p><p>...just an interesting way some of us have been looking at it.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 5932959"]Yeah thats all great marketing material, and maybe Arthur uses that in his Q3 earnings call. What Nucynta is doing in Europe has nothing to do with anything unfortunately. Whole diff ball game. Nucynta is no where near as expensive in Europe which is one of the biggest factors here. Despite all these great talking points, the fact of the matter is (and this is from our call last week), scripts are declining. Basically we are looking at it like this: 1. The patient has to find a doctor who will actually prescribe Nucynta 2. The patients has to actually have insurance that will cover it, few can afford Nucynta out of pocket 3. If the patient finally gets this far they have to find a pharmacy that will fill it So on all 3 fronts you have doctors, insurance companies, and pharmacies all trying to do their part to block a Nucynta sale. Making a sale is a maze, and not everyone is going to get through. Some get #1, but then get suck on #2. #3 is seen as minimal but growing risk with CVS and Walgreens trying to hop on the bandwagon and block peoples meds. Basically at the end of the quarter, the Nucynta script count is total number of people in this country who made it through the maze. ...just an interesting way some of us have been looking at it.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Depomed
>
Stock price
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Depomed
>
Stock price
>